92
Views
29
CrossRef citations to date
0
Altmetric
Research Article

Sesquiterpene lactone fraction from Artemisia khorassanica inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression through the inactivation of NF-κB

, , , &
Pages 688-695 | Received 13 Dec 2009, Accepted 04 Feb 2010, Published online: 17 Mar 2010
 

Abstract

Objective: Members of the Artemisia genus (Astraceae) are important medicinal plants throughout the world. Here, we prepared a sesquiterpene lactone fraction from Artemisia khorassanica (SLAK) and evaluated its effect on inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) expression, and nuclear factor-κB (NF-κB) activity.

Methods: The effects of SLAK on lipopolysaccharide (LPS)-induced NO, prostaglandin E2 (PGE2), tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) production was evaluated in mouse macrophage J774A.1 cells. Moreover, we evaluated SLAK modulation of iNOS and COX-2 enzyme expression by western blot analysis.

Results: Our data revealed that SLAK (10–100 μg/mL), in a dose-dependent manner, inhibits NO, PGE2, TNF-α, and IL-1β production induced by LPS in the J774A.1 cells. These data were consistent with the modulation of iNOS and COX-2 expressions. It was also showed that SLAK suppresses the iNOS and COX-2 enzyme expression through the inhibition of NF-κB activity.

Conclusion: In this study, we demonstrated that SLAK inhibits the production of NO, PGE2, TNF-α, and IL-1β in LPS-stimulated macrophages. This anti-inflammatory effect possibly occurs by inhibiting iNOS and COX-2 expression via the inactivation of NF-κB pathway.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.